BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Tislelizumab: trial readouts and FDA decisions

4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: BeOne Medicines, FindCure Biosciences (ZhongShan) Co., Ltd., AskGene Pharma, Inc., Novartis Pharmaceuticals, BeiGene, Jazz Pharmaceuticals. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-01 est.P1/P2FindCure Biosciences (ZhongShan) Co., Ltd.NCT06499350 A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid TumorsAdvanced Malignant Solid Tumorsrecruiting33
2026-12-30 est.P3AskGene Pharma, Inc.NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaGastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinomaactive not recruiting780
2026-12-31 est.P3BeOne Medicines ONCNCT04170283 A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutiniB-cell Malignanciesactive not recruiting955
2027-01-25 est.P1/P2Novartis Pharmaceuticals NVSNCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lungactive not recruiting344

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2BeiGeneNCT03736889 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsMSI-H/dMMR Solid Tumorsrecruiting200
2026-07-15P3Jazz Pharmaceuticals JAZZNCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinomaactive not recruiting920
2026-05-23P3BeOne Medicines ONCNCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesAdvanced Malignanciescompleted404

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.